630.90 -4.65 (-0.73%)
NSEFeb 26, 2021 03:31 PM
The 3 reports from 1 analysts offering long term price targets for Aarti Drugs Ltd. have an average target of 812.00. The consensus estimate represents an upside of 28.71% from the last price of 630.90.
|Summary||Date||Stock||Broker||Price at Reco.||Target||Price at reco|
Change since reco(%)
|2021-01-28||Aarti Drugs Ltd. +||Axis Direct||686.90||812.00||686.90 (-8.15%)||28.71||Buy|
|2020-12-07||Aarti Drugs Ltd. +||Axis Direct||789.95||825.00||789.95 (-20.13%)||30.77||Buy|
ARTD is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs) Pharma Intermediates and Specialty Chemicals. Products under APIs includes Ciprofloxacin, Hydrochloride, Metronidazole, Metformin HCL, etc. whereas Specialty Chemicals includes Benzene Sulphonyl Chloride, Methyl Nicotin
|2020-10-27||Aarti Drugs Ltd. +||Axis Direct||677.20||812.00||677.20 (-6.84%)||28.71||Buy|
|2018-10-04||Aarti Drugs Ltd. +||Centrum Broking||553.00||910.00||553.00 (14.09%)||Pre-Bonus/|
We maintain our Buy rating on Aarti Drugs (ADL) and retain the TP to Rs910 based on 16x March'20 EPS of Rs56.8. ADL is the market leader in 9 out of 10 APIs manufactured by the company. That said, the company is likely to benefit from vertical integration which is likely to drive future growth. We expect margins to improve post the launch of new products and additional capacities of Ciprofloxacin and Metformin APIs in place. Key risks to our assumptions include...
|2018-05-17||Aarti Drugs Ltd. +||Centrum Broking||529.00||960.00||529.00 (19.26%)||Pre-Bonus/|
We maintain our Buy rating on Aarti Drugs (ADL) and revise the TP to Rs960 (earlier TP Rs940) based on 16x March'20 EPS of Rs60.1. AIL's Q4FY18 results exceeded our expectations. The pharma major's revenue grew 3% YoY, margin improved 260bps to 17.1% and net profit grew 10% YoY. That said, the company is likely to benefit from vertical integration which is likely to drive future growth. We expect margins to improve post the launch of new products and additional capacities of Ciprofloxacin and Metformin APIs coming on stream. Key risks to our assumptions include slowdown in the domestic pharma market and regulatory...
|2018-01-15||Aarti Drugs Ltd. +||Centrum Broking||697.00||940.00||697.00 (-9.48%)||Pre-Bonus/|
Valuation and key risks: We see strong scope for re-rating and ADL using our conservative five-year AOCF/EV yield method to arrive at a TP of Rs940, implying an upside of 25% over CMP. We expect the company to report RoE of 23% and RoCE of 15% for FY20. ADL outscores many of its peers due to its efficacious presence in the domestic and emerging markets and its integration across the value chain. Key risks to our call include slowdown in the domestic market and regulatory risks for its...